FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.
Page 34 of 40
Feb 21, 2026The investigation by Nature Medicine into reported inconsistencies in the study raises critical questions about the optimal timing of immunotherapy for cancer treatment and the broader implications for clinical practice and research integrity.
Feb 20, 2026The FDA is currently navigating intense internal and external pressures as public scrutiny mounts in response to decisions affecting vaccine approvals and regulatory oversight. The involvement of President Trump signals the critical nature of these challenges for both regulatory credibility and public health policy.
Feb 20, 2026The FDA’s Center for Drug Evaluation and Research (CDER) has entered a phase of enhanced scrutiny with Tracy Beth Høeg at its helm. Her inaugural address to FDA staffers outlined forthcoming investigations into the safety profiles of selective serotonin reuptake inhibitors (SSRIs) taken during pregnancy and the use of RSV antibodies in infant populations. This blog unpacks her regulatory approach, the context of these medications, and the broader implications for pharmaceutical oversight.
Feb 20, 2026The lawsuit filed by the Texas Attorney General targets Sanofi for allegedly incentivizing physicians to prescribe its medications through a system of benefits including free nursing services and insurance facilitation. This action sheds light on ongoing concerns about pharmaceutical marketing practices and regulatory oversight.
Feb 18, 2026Following the departure of Jim O’Neill, Jay Bhattacharya steps in as the latest acting CDC chief. This leadership change comes at a critical juncture, with implications for public health policies, agency direction, and the CDC's role in responding to emerging health issues.
Feb 17, 2026The journey of bitopertin, a drug targeting erythropoietic protoporphyria, illustrates the hurdles biotech companies face in regulatory pathways, especially when protocols are crafted with insights from previous FDA leaders. This article analyzes the implications of such influences on approval prospects and the innovation landscape in rare disease treatments.
Feb 17, 2026Moderna's recent mRNA vaccine rejection by the FDA spotlights the challenging and shifting regulatory landscape in the United States for novel drug modalities. Meanwhile, regulatory agencies in other countries are adopting more streamlined communication and approval paths, facilitating faster adoption of advanced therapies. This post examines the implications of these regulatory dynamics for the broader advanced therapies market and global drug development strategies.
Feb 16, 2026As artificial intelligence rapidly becomes an essential tool in drug development and regulatory review, the Drug Information Association (DIA) is actively bridging the gap between high-level AI principles and everyday regulatory practices. This article explores DIA’s initiatives and their impact on streamlining regulatory processes while ensuring safety and efficacy in medical innovation.
Feb 15, 2026The Centers for Disease Control and Prevention (CDC) is currently navigating a turbulent period marked by leadership instability. The departure of the acting director has intensified concerns over the agency’s capability to manage public health effectively without confirmed leadership at the helm.
Feb 15, 2026Disc Medicine’s recent setback with its rare disease therapy approval accentuates the hurdles faced by developers within the rare disease space. Regulatory scrutiny remains stringent as agencies balance patient needs with safety and efficacy standards.
Feb 14, 2026A high-profile courtroom dispute unfolded involving pediatricians' group contesting policy alterations made by HHS under Robert F. Kennedy Jr. The case centers on alleged unlawful modifications impacting vaccine protocols, sparking significant debate within public health and policy circles.
Feb 13, 2026PTC Therapeutics announced it will no longer pursue FDA approval for Translarna, a rare disease drug targeting Duchenne muscular dystrophy. This decision follows a year marked by regulatory hurdles starting with a negative ruling from European authorities. The company cited significant discrepancies with the FDA over the interpretation of clinical trial results as the primary cause for withdrawal.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.